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ABSTRACT
Objective: The objective of this study was to investigate the association between proinflammatory cytokines in special, the interleukin-6 (IL-6), and 
insulin-like growth factor (IGF-1) levels in coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM).
Methods: This study was conducted from November 2017 to March 2018 in Anbar, Iraq. We studied a total of 90 individuals (46 men and 44 women) 
aged between 20 and 87 years. The samples were divided into four groups: CAD patients (n=23), T2DM patients (n=23), coronary artery disease 
and type 2 diabetes together in the same patient (n=23), and control group (n=21). The concentrations of IL-6 and IGF-1 were determined using a 
commercially available enzyme-linked immune sorbent assay.
Results: The results of the present study showed that there were elevated serum levels of IL-6 and low levels of IGF-1 in all the tested groups, 
compared with the control. The difference was statistically significant at p<0.05. The results showed a positively correlated between IL-6 and IGF-1 in 
the CAD group and T2DM group, while it was a negative correlation between serum levels of IL-6 and IGF-1 in the T2DM+CAD group.
Conclusion: Elevated levels serum of IL-6 predicts the development of CAD and T2DM. These data support a possible role for inflammation in 
diabetogenesis and complication of the cardiovascular disease. There is an inverse relationship between the levels serum of IGF-1 and increased risk 
of CAD and development of T2DM.
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INTRODUCTION
Coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) 
are the common health problems. These two diseases are one of the 
main causes of mortality around the world. In 2010, approximately 
8.3 million people were died due to these diseases, almost one in six 
deaths worldwide. In the last decades, the prevalence of CAD and T2DM 
has an increased greatly [1]. Although the main cause for this increase 
remains unclear, the primary reason maybe is chronic low-grade 
inflammation and an activation of the innate immunity system [2].
The main cause of CAD is atherosclerosis, which occurs because of plaque 
buildup which leads to narrowing bloodstream of the coronary arteries 
that supply the myocardium with blood. This problem leads to lack of blood 
flow and shows symptom ischemia [3]. CAD is considered as a chronic and 
very common disorder with conventional and genetic danger factors. The 
conventional risk factors for CAD involve obesity, age, dyslipidemia, gender, 
smoking, hypertension, and diabetes. These factors act autonomously or in 
concert together to increase the danger of the CAD [4].
The term T2DM describes insulin secretion deficiency due to 
pancreatic β-cell dysfunction and impaired insulin receptors and 
insulin action [5]. T2DM develops due to the collective action of both 
insufficient insulin secretion and insulin resistance (IR) [6]. There are 
many factors increased the risk of T2DM such as a family history of 
diabetes and environmental factors [7,8]. Other studies have shown 
that there was a strong association between type 2 diabetes, CAD, 
and inflammatory markers. The increase of macrophages in adipose 
tissue, the predominant presence of peripheral mononuclear cells, and 
apoptotic β-cells by themselves may be the causes of inflammation 
present in T2DM since they create the mediators of the inflammatory 
processes, i.e., cytokines [9]. Interleukin-6 (IL-6) is a multifunctional 
cytokine that owns a broad range of activities. The main role for IL-6 
in inflammatory is hematopoiesis and regulating the immune response. 
There are several cells that are responsible of producing IL-6 including 
T and B cells, endothelial cells, monocytes/macrophages, fibroblasts, 
and adipocytes [10,11].
Increase generation of IL-6 involves the progression of CAD because 
raised IL-6 levels are associated with increased risk and ferocity of 
CAD [12]. Inflammatory biomarkers are one of the signs that predict 
the onset of cardiovascular events [13]. 
The important value of these markers, including (IL-6), has been 
demonstrated for patients suffering from CAD [14]. In addition, several 
studies have been shown high levels of IL-6 in insulin-resistant states 
such as obesity, impaired glucose tolerance (IGT), and T2DM [15]. As 
other studies have shown, a strong relationship found between IL-6 and 
levels of glucose was an important predictor of type 2 diabetes in at-risk 
individuals. Inability in glucose control and its link with inflammation 
in diabetes mellitus cause CAD, decline lung functions, and cause 
cardiovascular disorder [16].
The insulin-like growth factor 1 (IGF-1) is a small peptide of 7.6 kDa, 
which is composed of 70 amino acids and similar 50% structure of 
insulin [17]. IGF-1 plays important roles in controlling proliferation, 
metabolism, differentiation, and cell survival. It is producing by the liver 
in response to growth hormone. However, other tissues also a synthesis 
of IGF-1, which works as a paracrine hormone and autocrine. At the 
cellular grade, IGF-1 can act in another subcellular compartment. It is, 
therefore, necessary to understand the complication of IGF-1 signaling 
and its role in the onset and progress of disease. Particularly in the 
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heart, several cellular processes can be regulated by IGF-1 including 
apoptosis, aging, metabolism, growth, and autophagy [18,19]. There is 
a study suggest decreasing IGF-1 levels to be a sign of diabetes [20].
There is some contradiction in the findings of the studies; one study 
found a positive association with reducing serum IGF-1 [21] while 
the another study did not find an association [22]. There is negatively 
relationship between serum IGF-1 levels and risk of developing 
CAD [18]. A low level of serum IGF-1 is associated with a risen risk of 
CAD and has been utilized as a signal for ischemic. Similarly, elderly 
patients showing low serum IGF-1 levels with an increased risk of heart 
failure and ischemic stroke [19,23].
METHODS
This study was conducted from November 2017 to March 2018 in Anbar, 
Iraq. We studied a total of 90 subjects (46 men and 44 women) aged 
between 20 and 87 years divided into four groups: CAD patients (n=23), 
T2DM patients (n=23), coronary artery disease and type 2 diabetes 
together in the same patient (n=23), and control group (n=21) who had 
no evidence of CAD or T2DM. Venous blood samples of all the groups 
(patients and control) were drawn using plastic disposable syringes 
placed into gel tubes and separated by centrifugation at 3000 rpm 
for 15 min. After that, serum was decanted and stored at −20°C until 
assayed. The concentrations of IL-6 and IGF-1 were determined using a 
commercially available enzyme-linked immune sorbent assay (ELISA) 
based on biotin double antibody sandwich technology, ELISA kit (Gen 
Asia) GA-E0130HM and GA-E0143HM, respectively, according to the 
manufacturer’s instructions. The range of detection was 0–2500 pg/ml 
for IL-6 and 0.1–40 ng/ml for IGF-1.
RESULTS
Table 1 shows the serum levels of IL-6 in different groups of patients. 
Serum levels of IL-6 in patients with CAD (310.30±125.96 pg/ml; p<0.05) 
and T2DM+CAD (479.87±216.56 pg/ml; p<0.05) were increased 
compared with the control (137.38±35.49 pg/ml). The difference was 
statistically significant at p<0.05. As for the serum level of IL-6 was 
also analyzed in patients with T2DM and although the values were 
higher in this group (216.83±80.60 pg/ml; p<0.05), compared with 
the control (137.38±35.49 pg/ml), the difference was not statistically 
considerable.
However, Table 2 appears the low levels of IGF-1 in the T2DM, CAD, and 
T2DM+CAD groups compared with those in controls (12.09±4.77 vs. 
28.81±4.84 ng/ml; p<0.05, 13.74±4.65 vs. 28.81±4.84 ng/ml; p<0.05, 
and 11.57±4.19 vs. 28.81±4.84 ng/ml; p<0.05, respectively). This 
difference was statistically worthy.
Regarding the study of the effect of sex on levels of serum IL-6 and 
IGF-1, the t-test showed no significant differences in the values 
of serum IL-6 and IGF-1 between the males and females of the 
T2DM group where the values in males are 218.44±86.54 pg/ml 
and 14.11±5.18 ng/ml; p<0.05, respectively, and in the females are 
215.79±79.90 pg/ml and 10.79±4.15 ng/ml; p<0.05, consecutive. On the 
other hand, there were expressive differences in the values of serum IL-6 
and IGF-1 in both genders in the CAD group where the values in males 
are 361.62±112.04 pg/ml and 15.62±4.44 ng/ml; p<0.05, successive, 
and in the females are 243.60±115.33 pg/ml and 11.30±3.86 ng/ml; 
p<0.05, sequent. In addition, there were worthy differences in the values 
of serum IL-6 between males and females in the DM+CAD group. The 
values in the males were 381.36±212.31 pg/ml; p<0.05 and females 
were 570.17±184.98 pg/ml; p<0.05, but there were no significant 
differences in the values of serum IGF-1, the values in the males are 
12.73±4.29 ng/ml; p<0.05 and in the females are 10.50±3.97 ng/ml; 
p<0.05 (Table 3).
Turning to study of the relationship of hypertension with levels of 
serum IL-6 and IGF-1, there are differences in the mean values of serum 
IL-6 and IGF-1 in all the tested groups. Serum levels of IL-6 and IGF-1 in 
patients that do not suffer from hypertension with the T2DM group are 
223.38±85.22 pg/ml and 11.85±5.11 ng/ml; p<0.05, consecutive. While 
in patients that suffer from hypertension are 208.30±77.82 pg/ml and 
12.40±4.53 ng/ml, respectively. As for the patients that do not suffer 
from hypertension with CAD group, the values are 358.67±134.19 pg/ml 
and 13.50±5.75 ng/ml; p<0.05, successive, and in patients that suffer 
from hypertension are 293.24±122.49 pg/ml and 13.82±4.41 ng/ml; 
p<0.05, respectively. In addition, the values of the levels serum IL-6 and 
IGF-1 in the patients that do not suffer from hypertension with type 2 
diabetes and CADs T2DM+CAD group were 443.20±275.09 pg/ml 
and 13.40±3.85 ng/ml; p<0.05, successive, and in persons that suffer 
from hypertension were 490.06±205.86 pg/ml and 11.06±4.24 ng/ml; 
p<0.05, consecutive. Although there are differences in the mean values 
Table 1: Serum levels of IL‑6 in all the tested groups
Groups IL‑6 (pg/ml)
n Mean±SD p<0.05
T2DM 23 216.83±80.60 a
CAD 23 310.30±125.96 b
CAD+T2DM 23 479.87±216.56 c
Control 21 137.38±35.49 a
Total 90 289.40±183.59
T2DM: Type 2 diabetes mellitus, CAD: Coronary artery disease, SD: Standard 
deviation, IL-6: Interleukin-6
Table 2: Serum levels of the IGF‑1 in all the tested groups
Groups N IGF‑1 (ng/ml) p<0.05
Mean±SD
T2DM 23 12.09±4.77 a
CAD 23 13.74±4.65 a
CAD+T2DM 23 11.57±4.19 a
Control 21 28.81±4.84 b
Total 90 16.28±8.34
T2DM: Type 2 diabetes mellitus, CAD: Coronary artery disease, SD: Standard 
deviation, IGF-1: Insulin-like growth factor
Table 3: The association between serum levels of IL‑6, IGF‑1, 
and gender in all the tested groups
Groups n Mean±SD t‑test p value
T2DM
IL-6
Male 9 218.44±86.54 0.075 0.941
Female 14 215.79±79.90
IGF-1




Male 13 361.62±112.04 2.473 0.022
Female 10 243.60±115.33
IGF-1




Male 11 381.36±212.31 −2.279 0.033
Female 12 570.17±184.98
IGF-1
Male 11 12.73±4.29 1.294 0.210
Female 12 10.50±3.97
The t-test is significant at the 0.05 level or less. T2DM: Type 2 diabetes mellitus, 
SD: Standard deviation, CAD: Coronary artery disease, IL-6: Interleukin-6, 
IGF-1: Insulin-like growth factor
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and standard deviation values of serum IL-6 and IGF-1, the difference 
was not statistically significant (Table 4).
Correlations among the IL‑6 and IGF‑1
As shown in Fig. 1, IL-6 was positively correlated with serum levels of 
IGF-1in the T2DM group (r=0.019, p<0.05), although there was positively 
correlated, it is not statistically considerable at p<0.05 (Table 5).
A positive correlation was also observed between serum levels of IL-6 
and IGF-1 in the CAD group (r=0.266 p<0.05) as shown in Fig. 2. It was 
statistically significant at p<0.05 (Table 5). While it was a negative 
correlation between serum levels of IL-6 and IGF-1 in the T2DM+CAD 
group (r =0.070 p<0.05) as shown in (Fig. 3). It is not statistically 
expressive at p<0.05.
DISCUSSION
CAD is a disorder characterized by atherosclerosis of the heart arteries 
(blood vessels responsible for supplying the heart with blood). The 
slowly narrowing the vessel walls that transport blood to the heart 
its major reason for this disease, by lipid plaques that lead to show 
symptom ischemia (occlusion or narrowing the blood vessel) causes 
a lack nutrient and oxygen supply to the heart muscle [24]. T2DM is 
a major risk factor for the development of CAD [25]. The studies have 
confirmed that cardiovascular complexities are essentially or partially 
dependent on sustained chronic hyperglycemia [26].
It is explicit that changes in classical risk factors such as raised blood 
pressure and abnormal lipids alone cannot describe the excess rate 
of CAD in patients with type 2 diabetes. In addition, the chronic 
subclinical vascular inflammation is one of the reasons that play a role 
in the pathogenesis of CAD, insulin resistance (IR), and T2DM [27]. The 
markers of subclinical inflammation, include the IL-6, have been shown 
to be important independent predictors of T2DM and CAD risk [28]. 
Several studies have reported establish of decreased IGF-1 levels 
and its relation to insulin sensitivity and to type 2 diabetes. It is well 
documented that in human patients, low levels of IGF-1 significantly 
increase the risk for cardiovascular [18,20].
The present study showed increase concentrations of the pro-inflammatory 
cytokines IL-6 in the serum of all the tested groups (CAD, T2DM, and CAD 
and type 2 diabetes together in the same patient groups) compared to the 
control group. This agrees with previous studies which showed high levels 
of serum IL-6 in CAD and T2DM patients, compare to controls group [28].
However, lower serum IGF-1 concentrations have been found in 
patients (CAD, T2DM, and CAD+T2DM) compared with the control 
group. This agrees with previous several studies which have analyzed 
the relationship between IGF-I and CAD and T2DM [18,20]. There is 
some contradiction in the findings of the studies; one study found a 
positive association with reducing serum IGF-1 [21] while the another 
Table 4: The relationship of hypertension with levels of serum 
IL‑6 and IGF‑1 in all the tested groups
Groups n Mean±SD t‑test p value
T2DM
IL-6
Normal 13 223.38±85.22 0.437 0.667
Abnormal 10 208.30±77.82
IGF-1




Normal 6 358.67±134.19 1.099 0.284
Abnormal 17 293.24±122.49
IGF-1




Normal 5 443.20±275.09 −0.420 0.679
Abnormal 18 490.06±205.86
IGF-1
Normal 5 13.40±3.85 1.114 0.278
Abnormal 18 11.06±4.24
The t-test is significant at the 0.05 level or less. IL-6: Interleukin-6, 
IGF-1: Insulin-like growth factor, SD: Standard deviation
Fig. 1: Correlation between interleukin‑6 and insulin‑like growth 
factor in Type 2 diabetes mellitus group













*Correlation is significant at the 0.05 level (two-tailed). T2DM: Type 2 
diabetes mellitus, SD: Standard deviation, CAD: Coronary artery disease, 
IL-6: Interleukin-6, IGF-1: Insulin-like growth factor
Fig. 2: Correlation between interleukin‑6 and insulin‑like growth 
factor in coronary artery disease group
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study did not find an association [22]. There is a negative relationship 
between serum IGF-1 levels and risk of developing CAD [18]. In this 
study, we report a positive correlation among both IL-6 and IGF in 
the T2DM group and CAD group, this incompatibility with previous 
studies but showing a negative correlation in the T2DM+CAD group, 
this in agreement with study by Succurro et al. [29]. IGF-1 has anti-
inflammatory effects and lessening expression of pro-inflammatory 
cytokines like (IL-6) [30]. There are also data in animal models 
that reports state that IL-6 reduces IGF-I levels by increasing its 
clearance [31].
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